Icon

Fosamax - (70 mg/ 75 ml; Oral solution)

Alendronate Sodium Merck
70 mg/ 75 ml; Oral solution
Less Than $1000 mn
Less Than 5
None
None None
Less Than 5
Less Than 5
Treatment and prevention of osteoporosis
Yes
** ******* *** ******* ** **** ******* *********. **** ***** *** ******** ***** ******** *** ******** *** ******* ** *** ****.
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*****
  1. *** *, **** : * **** ** ** ***** *** ******* ** ******* *** *******.
  2. *** **, **** : ***** ******** ***** ******** *** ******** *** *******

Fosamax - (5, 10, 35, 40, 70 mg; Tablet, Oral )

Alendronate Sodium Merck
5, 10, 35, 40, 70 mg; Tablet, Oral
Less Than $1000 mn
None
Less Than 5
None None
More Than 5
Less Than 5
Treatment and prevention of osteoporosis
Yes
Fosamax Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9
**** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* *** ********* *** *********
******** ******* ******* ******* ******* ******* ******* ******* ******* *******
****** ******* ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** ***/*** *** *,**** ******* ******** ************ *********
******** **\** *** *,**** ******* ******** *** ****** *** ****
****** **\** *** *,**** ******* ******** *** ****** *** ****
  1. *** *, **** : ***** ***** * **** ******* **** ** *** ** ** ******** **** *** **** ****** **** ****** '*** ( **** *** ****)
  2. *** **, **** : ********* ** ****** ** *****, **** ******* ** **
  3. *** **, **** : ********** ********* **** ****
  4. *** *, **** : ***** ***** ***** ******* ******** (******) ** *** ** ** ******** *** **** ****** **** ******* ’*** (**** *, ****), ’*** (**** *, ****), ’*** (******** *, ****), ’*** (******** *, ****), ’*** (**** *, ****), ’*** (**** *, ****), ’***(******* **, ****), ’*** (******* **, ****), *** ’*** (******* **, ****) ********* *, **, **, ***, ** ** **** *******
  5. *** *, **** : ********** **** ******** ** ********* **** ********* *** **** ** ******* ****** ************
  6. *** **, **** : ****** ******** ***** ***** *** **** ** ****** **** ******* ’*** (**** *, ****), ’*** (**** *, ****), ’*** (******** *, ****), ’*** (******** *, ****), ’*** (**** *, ****), ’*** (**** *, ****), ’***(******* **, ****), ’*** (******* **, ****), *** ’*** (******* **, ****) *** *, **, **, ** ** *******
  7. *** *, **** : ***** ***** * **** ******* ****** ** ** ** ********
  8. *** **, **** : ********** **** ****** ** *********, ****** ******** ** *** ****** ** **
  9. *** *, **** : ** ** ********'* ********* ** ******** ** ****, ******* ** **** *** ******** ** **

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.